RecruitingPhase 3NCT06960213
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
Studying Hereditary angioedema
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- ADARx Pharmaceuticals, Inc.
- Principal Investigator
- Lauge Farnaes, MDADARx Pharmaceuticals, Inc.
- Intervention
- ADX-324(drug)
- Enrollment
- 90 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2027
Study locations (14)
- ADARx Clinical Site, Little Rock, Arkansas, United States
- ADARx Clinical Site, Walnut Creek, California, United States
- ADARx Clinical Site, Wheaton, Maryland, United States
- ADARx Clinical Site, Detroit, Michigan, United States
- ADARx Clinical Site, St Louis, Missouri, United States
- ADARx Clinical Site, Las Vegas, Nevada, United States
- ADARx Clinical Site, New York, New York, United States
- ADARx Clinical Site, Cincinnati, Ohio, United States
- ADARx Clinical Site, Columbus, Ohio, United States
- ADARx Clinical Site, Toledo, Ohio, United States
- ADARx Clinical Site, Ottawa, Ontario, Canada
- ADARx Clinical Site, Hradec Králové, Czechia
- ADARx Clinical Site, Budapest, Hungary
- ADARx Clinical Site, Madrid, Spain
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06960213 on ClinicalTrials.govOther trials for Hereditary angioedema
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07298447Donidalorsen Treatment in Children With Hereditary AngioedemaIonis Pharmaceuticals, Inc.
- RECRUITINGNANCT07559630Single-center Randomized Controlled Trial of Rectal Arterial Embolization vs Band Ligation for the Treatment of Internal hemOrrhoidSJessica K. Stewart, MD
- RECRUITINGPHASE3NCT07428499Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)ADARx Pharmaceuticals, Inc.
- RECRUITINGNANCT07251933A Study of Lanadelumab in Children With Hereditary Angioedema (HAE) in Multiple CountriesTakeda
- ENROLLING BY INVITATIONPHASE3NCT07204938A Long-Term Study of Navenibart in Participants With Hereditary AngioedemaAstria Therapeutics, Inc.
- RECRUITINGNANCT07001280A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)CSL Behring
- RECRUITINGPHASE3NCT06842823A Study of Navenibart in Participants With Hereditary AngioedemaAstria Therapeutics, Inc.
- RECRUITINGPHASE4NCT06806657Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to GaradacimabCSL Behring